Treatment outcome by assigned therapy
| . | HDAC/DNR, n = 40 . | HDAC/DNR + CsA, n = 37 . | ||
|---|---|---|---|---|
| Estimate . | 95% CI . | Estimate . | 95% CI . | |
| Median survival, mos, P = .77‡ | 5 | 4 -7 | 3 | 2 -5 |
| 6-mo survival probability, % | 47 | 37 -62 | 32 | 17 -48 |
| Complete response, P = .95‡ | 18 | 7 -33 | 5 | 1 -18 |
| Complete response or RCP, P = .99‡,4-151 | 30 | 17 -47 | 8 | 2 -22 |
| Resistant disease, P = .91‡ | 53 | 36 -68 | 68 | 50 -82 |
| . | HDAC/DNR, n = 40 . | HDAC/DNR + CsA, n = 37 . | ||
|---|---|---|---|---|
| Estimate . | 95% CI . | Estimate . | 95% CI . | |
| Median survival, mos, P = .77‡ | 5 | 4 -7 | 3 | 2 -5 |
| 6-mo survival probability, % | 47 | 37 -62 | 32 | 17 -48 |
| Complete response, P = .95‡ | 18 | 7 -33 | 5 | 1 -18 |
| Complete response or RCP, P = .99‡,4-151 | 30 | 17 -47 | 8 | 2 -22 |
| Resistant disease, P = .91‡ | 53 | 36 -68 | 68 | 50 -82 |
Undiff indicates undifferentiated; RCP, restored chronic phase.
Pgp expression was defined by flow cytometry detection of MRK16 reactivity with Kolmogorv-Smirnov (KS) D ≥ 0.20, MRP1 by MRPm6antibody with KS D ≥ 0.20, and LRP by the LRP56 antibody with KS D ≥ 0.25.
CsA-inhibited DiOC2 efflux was defined by Kolmogorv-Smirnov D ≥ 0.25.
One-tailed P for superior outcome in CsA arm, based on PH or logistic regression models for survival and response, respectively, adjusted for stratification by age group and blast lineage (lymphoid and undifferentiated combined in analyses of response).